NasdaqGS:APLSBiotechs
Apellis Pharmaceuticals (APLS): Discounted Valuation Reinforces Bullish Narrative Ahead of Profitability Targets
Apellis Pharmaceuticals (APLS) is currently unprofitable, but over the past five years, it has steadily trimmed its losses at a rate of 12% per year. Looking ahead, earnings are projected to grow 66.69% annually, with the company expected to reach profitability within three years. Revenue is forecast to rise by 13% per year, outpacing the broader U.S. market’s 10.3% growth rate. The current share price of $20.73 sits well below its estimated fair value of $91.09 based on discounted cash flow...